Frontiers In Psychiatry

This book reviews key recent advances and new frontiers within psychiatric research and clinical practice. These advances either represent or are enabling paradigm shifts in the discipline and are influencing how we observe, derive and test hypotheses, and intervene. Progress in information technology is allowing the collection of scattered, fragmented data and the discovery of hidden meanings from stored data, and the impacts on psychiatry are fully explored. Detailed attention is also paid to the applications of artificial intelligence, machine learning, and data science technology in psychiatry and to their role in the development of new hypotheses, which in turn promise to lead to new discoveries and treatments. Emerging research methods for precision medicine are discussed, as are a variety of novel theoretical frameworks for research, such as theoretical psychiatry, the developmental approach to the definition of psychopathology, and the theory of constructed emotion. The concluding section considers novel interventions and treatment avenues, including psychobiotics, the use of neuromodulation to augment cognitive control of emotion, and the role of the telomere-telomerase system in psychopharmacological interventions.

With chapters that focus on developing a robust therapeutic alliance and inspiring patients to assume responsibility for their own well-being, this guide provides a framework for lasting, sustainable lifestyle changes.

Psychiatric symptoms are considered to be distributed along a continuum, from good mental health to a diagnosable psychiatric disorder. In the case of psychosis, subclinical psychotic experiences, which can include odd behaviors, strange speech, unusual perceptual experiences and social/emotional withdrawal, are often referred to as schizotypy. Research examining schizotypal traits in non-clinical populations is rapidly expanding. The exploration of schizotypy allows us to identify areas of overlap with psychiatric disorders (schizophrenia and related disorders) at genetic, biological, environmental and psychosocial levels, thus identifying putative risk factors, as well as exploring potentially protective factors. Schizotypy is also a valuable model for exploring cognition as performance is not confounded by issues often present in schizophrenia samples, such as long-term antipsychotic medication usage, social isolation, and recurrent hospitalizations. Investigating cognition is a particularly important area of research as cognitive symptoms in schizophrenia, such as impaired attention, reduced memory and difficulties with executive functions, are a core feature of schizophrenia and strongly related to quality of life and functional outcomes, yet generally respond poorly to current treatment options. The aim of this special Research Topic is to explore the relationship between cognition, schizotypy and the schizophrenia spectrum. The articles in this e-book draw on a variety of perspectives and represent an interesting array of opinions, reviews and empirical studies that begin to answer questions about the similarities and overlaps between schizotypy and schizophrenia spectrum disorders, contributing to our understanding of potential risk factors. Equally important is research that highlights differences between schizotypy and schizophrenia spectrum disorders that may enhance our understanding of potentially protective or adaptive features of schizotypy. Collectively, these articles highlight the exploratory potential of the study of schizotypy, particularly in relation to better understanding cognition across the schizophrenia spectrum.

Disturbances of various domains of cognitive function have been shown to provide a major determinant of outcome for patients with psychiatric conditions. Cognitive impairment is present in an array of diseases, including schizophrenia (with its prodromal stage), mood disorder, autism spectrum disorder, obsessive-compulsive disorder, anxiety disorder, post-traumatic disorder, and eating disorder. In an effort to develop effective therapeutics for cognitive impairment, bridging of preclinical and clinical evidence has been attempted. This edited Book will provide a forum for researchers and clinicians interested in the phenomenology, underlying mechanisms, and treatment of cognitive impairment associated with psychiatric illnesses. Twenty-eight contributions from 8 countries in Europe, Middle East, Asia, North America, and South America represent studies dealing with genetic, molecular, imaging, physiological, psychological, and behavioral issues. Information in this Book will facilitate the development of therapeutics of greater clinical value.